Assessment of the drug metabolism capacity of the liver.
about
Interaction between vigabatrin and phenytoin.Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugsHanging Drop, A Best Three-Dimensional (3D) Culture Method for Primary Buffalo and Sheep Hepatocytes.The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction.Lack of effect of ketanserin on indices of hepatic enzyme induction.Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.D-glucaric acid excretion in critical care patients--comparison with 6 beta-hydroxycortisol excretion and serum gamma-glutamyltranspeptidase activity and relation to multiple drug therapyDebrisoquine oxidation in an Australian population.Pharmacokinetics of antipyrine in epileptic patientsAntipyrine clearance and metabolism in patients with psoriasis.Effect of chloroquine and primaquine on antipyrine metabolismHepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma.Drug metabolism and liver disease in India.Pharmacokinetics in special populations.Prediction of xenobiotic metabolism by non-invasive methods.Metronidazole and antipyrine as probes for the study of foreign compound metabolism.Noninvasive assessment of microsomal enzyme activity in occupational medicine: present state of knowledge and future perspectives.Biomimetic models for monooxygenases.Disposition of hexobarbital: 15 years of an intriguing model substrate.The assessment of flavin-containing monooxygenase activity in intact animals.Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat.Simplified approach for evaluation of hepatic drug-oxidizing capacity with a simultaneous measurement of caffeine and its primary demethylated metabolites in carbon tetrachloride-intoxicated rats.Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects.Age-related changes in trimethadione oxidizing capacity.Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing.Effects of cimetidine on carbamazepine auto- and hetero-induction in man.Cisapride has no effect on antipyrine clearance.Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy.The effect of chronic phenytoin treatment on serum lipid profile in adult epileptic patients.Use of salivary caffeine tests to assess the inducer effect of a drug on hepatic metabolism.
P2860
Q24540432-7254D914-C740-43F4-B76F-EA677CF6E264Q28365793-A39BC6A3-7D1C-4C1B-B145-64DCF41EDB54Q33683188-A595CEB5-783C-4A3C-B6B7-04100686CAD7Q34397888-1110DCBC-6895-4E3E-B34C-4BE1272CB34FQ34416967-AEE0C9FB-E61A-43C0-ADE8-54727F1B003DQ34417899-0660E52B-4940-4209-911A-84C198F38D94Q34418061-8F749333-5FDB-45CD-8D7C-85584EB138C6Q34446987-BCEB0689-7BFE-4CA9-8BCB-92F92DDC5FBEQ34447633-B14E9B8E-7FE5-4C3E-AB87-4A44D08F09ECQ34447648-10A3356B-DEE3-4E21-852E-8C5BEF316E0EQ34448073-D6C4BDF8-9D93-4A41-AC8F-A38B6B00A404Q34513366-3B93C257-1FA2-4D79-A1A4-38759012A0E6Q34668452-1C50B8B9-5A6A-4AC0-B54B-C9C781BA52A4Q37238161-A3A4C078-A2BF-4AA0-B46F-FF1AA6D8BEBDQ37550561-777E2E6D-22B5-44B4-8853-B5759BB23E83Q37829237-B493139A-A84F-4FFF-A43A-001479E20D94Q37918077-24B1D83F-9FFC-4B7B-881A-1228C90AB7E4Q38522099-136F485F-33B1-4660-AB0F-613319814828Q38707733-3C1625D1-6F08-4F6B-82CB-81ED250F85FBQ39567059-04F86CA5-5B3B-4805-B85F-78B9EC17A58FQ41197123-81E8BC51-BE22-4C53-A740-84C6AC4FBAB9Q41747906-452C2FD5-98D5-4B77-BB8C-1F987F505698Q41765820-616B0113-4236-45ED-A7A1-52D7140B7E64Q41917893-5D44AD0C-40E9-4A9C-8F0A-DBAE91C25DA6Q42285148-8FBD617C-3419-43A3-8CBF-7E2A33185DCFQ42530969-A72D1ACF-B51D-4DD8-B02C-99F8C6F7EDD5Q42531502-A9100EA4-D4F8-446B-A693-E37DE7F9D34BQ43042356-A04C49D8-E2CC-4053-9B76-F400FC24F781Q43698020-3B1BFF42-B053-4B05-A8BC-1CADB6202E24Q44637757-B6F8C9FB-7C14-4C1B-8E7C-ECB06AE81F7BQ53985559-A2ADFFB0-F4F5-4CAE-81D9-6798D8796C91
P2860
Assessment of the drug metabolism capacity of the liver.
description
1982 nî lūn-bûn
@nan
1982 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1982 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
name
Assessment of the drug metabolism capacity of the liver.
@ast
Assessment of the drug metabolism capacity of the liver.
@en
Assessment of the drug metabolism capacity of the liver.
@nl
type
label
Assessment of the drug metabolism capacity of the liver.
@ast
Assessment of the drug metabolism capacity of the liver.
@en
Assessment of the drug metabolism capacity of the liver.
@nl
prefLabel
Assessment of the drug metabolism capacity of the liver.
@ast
Assessment of the drug metabolism capacity of the liver.
@en
Assessment of the drug metabolism capacity of the liver.
@nl
P2860
P1476
Assessment of the drug metabolism capacity of the liver.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1982.TB04950.X
P407
P577
1982-11-01T00:00:00Z